Compare Organon & Co. Common Stock (OGN) vs Qnity Electronics Inc. Common Stock (Q) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Qnity Electronics Inc. Common Stock — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while Qnity Electronics Inc. Common Stock trades at $119 (market cap $25.71B). The key difference: Qnity Electronics Inc. Common Stock is far larger — about 7.1× Organon & Co. Common Stock's market cap, and Organon & Co. Common Stock pays the higher dividend (0.58%). Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Qnity Electronics Inc. Common Stock for 6 Days on average.
| OGN | Q | |
|---|---|---|
Market Cap | $3.62B | $25.71B |
Volume | 2,892,999 | 1,883,674 |
Sector | Health | Technology |
52-Week High | $13.81 | $175.64 |
52-Week Low | $5.70 | $73.54 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $11.04B | $28.77B |
Dividend Yield | 0.58% | 0.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Qnity Electronics (Q) trades at $122.95, down 0.21% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue grew to $4.75B in 2025, though net income margin is expected to dip in 2026. Recent news highlights product launches in AI data center cooling and advanced packaging, alongside inclusion in the PHLX Semiconductor Index.
The stock presents a mixed outlook: strong analyst consensus (100% buy ratings) and a $180 price target suggest significant upside, but technical weakness and a high P/E ratio of 43.9 pose risks. Key opportunities include AI-driven demand and advanced packaging growth, while risks involve execution in a competitive semiconductor market and potential margin pressure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Qnity Electronics Inc. Common Stock
Qnity Electronics provides materials and solutions for semiconductor manufacturing and electronic systems. Its portfolio supports chip fabrication, advanced packaging, interconnects, and thermal management.
Read more on Q →
